Working… Menu

Anagrelide Retard in Essential Thrombocythemia (TEAM-ET)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02076815
Recruitment Status : Completed
First Posted : March 4, 2014
Last Update Posted : July 29, 2015
Information provided by (Responsible Party):
AOP Orphan Pharmaceuticals AG

Brief Summary:

The purpose of this study is determine whether Anagrelide Retard is non-inferior to anagrelide immediate release form in treatment of essential thrombocythemia.

Essential thrombocythemia (ET) is a myeloproliferative neoplasm characterised by a sustained increase in platelet counts above the normal value (> 450 x 109/L) and increased megakaryopoiesis in the bone marrow, without secondary causes of thrombocytosis.

Anagrelide hydrochloride selectively reduces platelet numbers by inhibiting megakaryocyte development and maturation in humans, without affecting other cell lineages.

Anagrelide Retard is a new, prolonged release (PR) tablet formulation of anagrelide developed by AOP Orphan Pharmaceuticals AG. The rationale for developing this new formulation is based on the assumption of having a better tolerability while maintaining an efficacy comparable to that of the immediate release formulation.

The effects of Anagrelide Retard and Thromboreductin® will be compared in terms of mean platelet count measured by a central laboratory/centralized method at 3 time points during the maintenance phase.

Condition or disease Intervention/treatment Phase
Essential Thrombocythemia Drug: Anagrelide retard Drug: Thromboreductin Phase 3

Detailed Description:

This is a randomised, multicentre, double-blind, active controlled study to compare the efficacy and safety of two different anagrelide formulations in patients with high-risk essential thrombocythemia (ET).

100 patients, either Anagrelide-treated or Anagrelide-naïve, with an indication to receive Thromboreductin® treatment, will be randomized into one of the two investigational medicinal product (IMP) groups (Anagrelide Retard or Thromboreductin®). Treatment allocation will be balanced within stratum (treated/naive) and age classes by central randomization. Naive patients will start with dose level 2 of the IMPs (i.e., 1 mg Thromboreductin® or 2 mg Anagrelide Retard). Anagrelide-treated patients will be switched to the dose level which is closest to the pre-study anagrelide dose at study start. Dose modifications in the titration phase will be done on a weekly basis (up to a maximum of 12 weeks) until "stable platelet counts" on two consecutive visits is achieved.

The periods of the study participation per patient are as follows:

  • Screening (up to 7 days prior to randomization), ending with randomization/first IMP dose (Baseline Visit)
  • Titration period (weekly visits for up to 12 weeks): to achieve "stable platelet counts" on two consecutive measurements (i.e. weekly visits)
  • Maintenance period (weekly visits for 4 weeks): primary endpoint relevant period. The maintenance period for a patient starts at the visit with the second successive platelet count ≤400 G/L (or <600 G/L, if the dose cannot be increased any more due to intolerance or because the maximal dose allowed has already been reached) if the second platelet value measured lies in the range within ± 30% of the value measured at the previous visit.
  • End of study (EoS) safety follow-up visit (28 days after the last maintenance visit/EoT for early termination).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 106 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III Randomized, Multicenter, Double-blind, Active Controlled Study to Compare the Efficacy and Safety of Two Different Anagrelide Formulations in Patients With Essential Thrombocythemia (TEAM-ET 2.0)
Study Start Date : February 2014
Actual Primary Completion Date : February 2015
Actual Study Completion Date : April 2015

Arm Intervention/treatment
Experimental: Anagrelide retard
Anagrelide Retard prolonged-release formulation
Drug: Anagrelide retard
Overencapsulated tablets or matched placebo, twice daily, 2-12 weeks titration to achieve stable platelet count, followed by 4 more weeks
Other Names:
  • Anagrelide retard 2 mg film coated tablet
  • ANAT2

Active Comparator: Thromboreductin
Anagrelide immediate release formulation
Drug: Thromboreductin
Overencapsulated capsule, twice daily, 2-12 weeks titration to achieve the stable platelet count, followed by 4 more weeks
Other Names:
  • Anagrelide 0.5 mg capsule
  • ANAC05

Primary Outcome Measures :
  1. Platelet count [ Time Frame: weeks 13-17 ]
    Mean value from three measurements

Secondary Outcome Measures :
  1. platelet response [ Time Frame: weeks 13-17 ]
  2. Time from randomization to entering maintenance period [ Time Frame: up to 12 weeks ]
  3. Study drug administration [ Time Frame: weeks 1-17 ]
  4. Change in platelet counts in the titration period [ Time Frame: baseline, week 12 ]
  5. Time from randomization until withdrawal [ Time Frame: up to 17 weeks ]
  6. Incidence, causality and intensity of adverse events [ Time Frame: weeks 0-21 ]
  7. Incidence, intensity and outcomes of events leading to dose reduction or temporary or permanent treatment discontinuation [ Time Frame: weeks 1-18 ]
  8. Need of medications to treat adverse events [ Time Frame: weeks 0-21 ]
  9. ECG abnormalities [ Time Frame: weeks 0-18 ]
  10. Ejection fraction [ Time Frame: baseline, week 17, week 21 ]
  11. ECHO normal/abnormal [ Time Frame: baseline, week 17, week 21 ]

Other Outcome Measures:
  1. Quality of Life [ Time Frame: at week 1 and week 13 ]
  2. Plasma anagrelide concentration [ Time Frame: At week 13, 15 and 17 ]
  3. Plasma anagrelide concentration [ Time Frame: 1 min prior study treatment intake (morning dose), and 0.5, 1, 2, 3, 4, 6, 8, 10,12 (followed by evening dose), 13, 14, 15, 16, 18, 20, 24 hours after study treatment intake (morning dose) ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • willing and able to give written informed consent prior to any study specific procedures and able to comply with the trial protocol
  • confirmed diagnosis of ET according to 2008 WHO diagnostic criteria* (Swerdlow et al, 2008), defined as meeting all four criteria
  • at high risk of experiencing ET-related events, indicated for Thromboreductin® treatment as defined by one or more of the following criteria: age ≥ 60 years, platelet counts ≥ 1000 G/L, increase of platelet count ≥ 300 G/L within 3 months, severe thrombohemorrhagic or ischemic symptoms in anamnesis
  • either currently treated with anagrelide
  • or ET treatment naive
  • or anagrelide naive

Exclusion Criteria:

  • Diagnosis of any myeloproliferative disorder other than ET
  • Any known cause for a secondary thrombocytosis
  • ET currently well controlled by another cytoreductive treatment than Anagrelide and the opportunity to continue to receive this treatment
  • ET currently treated with combination of any two of the following agents: anagrelide, hydroxyurea, interferons, busulfan
  • Hypersensitivity to either active or non-active ingredients of anagrelide or to any other excipients of the investigational products
  • Known hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption
  • Cardiovascular disease grade 3 with a negative benefit/risk assessment or grade 4 (South West Oncology Group; Green and Weiss, 1992)
  • Clinically significant abnormal laboratory values (excluding markers for ET) in investigator's opinion
  • Severe renal insufficiency (creatinine clearance <30 ml/min)
  • Moderate to severe hepatic insufficiency (ALT or AST > 5 times upper normal limit [UNL])
  • White blood count (WBC) ≥ 15 G/L at screening
  • Diagnosis of any malignancy, other than ET (except basal cell and squamous cell carcinomas of the skin and carcinoma in situ of the cervix that have been completely excised and are considered cured), within the last 3 years, or coexisting malignant, systemic disease
  • Poorly controlled diabetes mellitus
  • Known infection with hepatitis B, hepatitis C or HIV
  • Pregnant or lactating women
  • Women of childbearing potential or male patients, who have sexual intercourse with females of childbearing potential, not willing to use an effective method of contraception during the study.
  • History of drug/alcohol abuse within the previous 2 years
  • Participation in another investigational study within 4 weeks prior to informed consent signed or for a longer duration if specified in local regulations
  • Any significant psychiatric disorder that, in the opinion of the investigator, might prohibit the understanding and giving of informed consent, or that might prevent the patient from completing the trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02076815

Layout table for location information
AOP Orphan Investigational Site Austria 2
Linz, Austria, A-4040
AOP Orphan Investigational Site Austria 1
Vienna, Austria, A-1090
AOP Orphan Investigational Site Austria 3
Wels, Austria, A-4600
AOP Orphan Investigational Site Bulgaria 1
Pleven, Bulgaria, 5800
AOP Orphan Investigational Site Bulgaria 2
Sofia, Bulgaria, 1407
AOP Orphan Investigational Site Lithuania 1
Kaunas, Lithuania, LT-50009
AOP Orphan Investigational Site Lithuania 2
Klaipeda, Lithuania, LT-92288
AOP Orphan Investigational Site Poland 5
Bialystok, Poland, 15-276
AOP Orphan Insvestigational Site Poland 6
Gdansk, Poland, 80-952
AOP Orphan Investigational Site Poland 4
Katowice, Poland, 40-027
AOP Orphan Investigational Site Poland 3
Lublin, Poland, 20-081
AOP Orphan Investigational Site Poland 2
Torun, Poland, 87-100
AOP Orphan Investigational Site Poland 1
Warsaw, Poland, 02-776
Russian Federation
AOP Orphan Investigational Site Russia 1
Moscow, Russian Federation, 125167
AOP Orphan Investigational Site Russia 2
Saint-Petersburg, Russian Federation, 191024
AOP Orphan Investigational Site Russia 5
Saint-Petersburg, Russian Federation, 194291
AOP Orphan Investigational Site Russia 4
Saint-Petersburg, Russian Federation, 196084
AOP Orphan Investigational Site Russia 6
Volgograd, Russian Federation, 400138
AOP Orphan Investigational Site Russia 3
Yaroslavl, Russian Federation, 150062
Sponsors and Collaborators
AOP Orphan Pharmaceuticals AG
Layout table for investigator information
Principal Investigator: Heinz Gisslinger, Prof., MD Vienna Medical University

Layout table for additonal information
Responsible Party: AOP Orphan Pharmaceuticals AG Identifier: NCT02076815     History of Changes
Other Study ID Numbers: AOP18007
2013-003410-41 ( EudraCT Number )
First Posted: March 4, 2014    Key Record Dates
Last Update Posted: July 29, 2015
Last Verified: July 2015
Keywords provided by AOP Orphan Pharmaceuticals AG:
myeloproliferative neoplasm
essential thrombocythemia
high risk patients
Additional relevant MeSH terms:
Layout table for MeSH terms
Thrombocythemia, Essential
Blood Platelet Disorders
Hematologic Diseases
Myeloproliferative Disorders
Bone Marrow Diseases
Blood Coagulation Disorders
Hemorrhagic Disorders
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors